Avoro Capital Advisors LLC Grows Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Avoro Capital Advisors LLC grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,628,822 shares of the company's stock after buying an additional 6,600 shares during the period. Krystal Biotech makes up 5.8% of Avoro Capital Advisors LLC's holdings, making the stock its 5th biggest position. Avoro Capital Advisors LLC owned 9.14% of Krystal Biotech worth $411,831,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of KRYS. Entropy Technologies LP bought a new position in Krystal Biotech during the 4th quarter worth $548,000. Janney Montgomery Scott LLC increased its position in shares of Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after purchasing an additional 15,545 shares during the period. Principal Financial Group Inc. raised its stake in Krystal Biotech by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after purchasing an additional 3,727 shares in the last quarter. abrdn plc lifted its position in Krystal Biotech by 32.5% during the fourth quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after purchasing an additional 13,979 shares during the period. Finally, Blue Trust Inc. grew its stake in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after buying an additional 433 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on KRYS shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Finally, Chardan Capital raised their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average target price of $220.00.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded down $1.06 on Friday, hitting $168.06. The stock had a trading volume of 171,300 shares, compared to its average volume of 295,591. The stock has a 50 day moving average of $176.37 and a 200 day moving average of $171.57. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The firm has a market capitalization of $4.86 billion, a P/E ratio of 56.21 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).